2 results
Approved WMORecruiting
To demonstrate the safety and efficacy of the SELUTION SLR* 014 DEB for treatment of bare-metal or drug-eluting in-stent restenosis (ISR).
Approved WMORecruiting
The primary endpoint is the evaluation of the safety and toxicity of TIL with nivolumab and, thereafter, the safety and toxicity of the combination of PEG-IFNa, nivolumab plus TIL. Safety and toxicity will be evaluated according to CTCAE 4.0…